TrumpRx.gov launches with 43 discounted drugs from 5 pharma giants. Wegovy drops to $199/mo, Zepbound to $299/mo. GLP-1 stocks extend losses.

TrumpRx Goes Live: GLP-1 Drug Prices Slashed Up to 85%, Pharma Stocks React

Eli Lilly Q4 revenue surges 43% to $19.3B, crushing estimates by 7%. Mounjaro and Zepbound sales double. 2026 guidance of $80-83B stuns Street.

Eli Lilly Crushes Q4 as Mounjaro and Zepbound Sales Double—Stock Surges 8%

Eli Lilly announces $3.5B Pennsylvania plant to make retatrutide, its triple-agonist obesity drug showing 24% weight loss in trials.

Eli Lilly Bets $3.5 Billion on Pennsylvania to Build Retatrutide Arsenal

Lilly pays up to $1.12B for Seamless Therapeutics' recombinase platform to expand hearing loss pipeline. Third major genetic medicine deal since 2022.

Eli Lilly Bets $1.12 Billion on Next-Gen Gene Editing for Hearing Loss

CMS names 15 drugs for Medicare price talks under IRA round 3, but analysts say impact is immaterial for most—except Gilead's Biktarvy at 8% revenue exposure.

Medicare Adds 15 Drugs to Price Negotiation: Biktarvy, Trulicity, Botox on the List

Roche's CT-388 shows 22.5% weight loss in Phase 2, matching Eli Lilly's Zepbound. Phase 3 trials start this quarter in $150B obesity market.

ELI LILLY & (LLY)·Earnings Reports

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Analyst Coverage

Recent News about ELI LILLY &

TrumpRx Goes Live: GLP-1 Drug Prices Slashed Up to 85%, Pharma Stocks React

Eli Lilly Crushes Q4 as Mounjaro and Zepbound Sales Double—Stock Surges 8%

Eli Lilly Bets $3.5 Billion on Pennsylvania to Build Retatrutide Arsenal

Eli Lilly Bets $1.12 Billion on Next-Gen Gene Editing for Hearing Loss

Medicare Adds 15 Drugs to Price Negotiation: Biktarvy, Trulicity, Botox on the List

Roche Enters $150 Billion Obesity Drug Race With 22.5% Weight Loss Data